Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 852, Issue 1-2, 2007, Pages 497-504

  Cabovska B ^a   Cox, S L ^a   Vinks, A A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

9 Hydroxyrisperidone enantiomers; LC MS MS method; Matrix effects; Risperidone

Indexed keywords

BIOASSAY; METABOLITES; PATIENT MONITORING; PHARMACOKINETICS; PLASMA (HUMAN);

MATRIX EFFECTS; PERVASIVE DEVELOPMENTAL DISORDER (PDD); RISPERIDONE;

ENANTIOMERS;

PALIPERIDONE; RISPERIDONE;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ENANTIOMER; HUMAN; ISOMER; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; RACEMIZATION;

CHILD; CHROMATOGRAPHY, LIQUID; HUMANS; ISOXAZOLES; PYRIMIDINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 34249659539     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.02.007     Document Type: Article

References (21)

1. He H., and Richardson J.S. Int. Clin. Psychopharmacol. 10 (1995) 19
2. Keegan D. Can. J. Psychiatry 39 (1994) S46
3. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., Arnold L.E., Lindsay R., Nash P., Hollway J., McDougle C.J., Posey D., Swiezy N., Kohn A., Scahill L., Martin A., Koenig K., Volkmar F., Carroll D., Lancor A., Tierney E., Ghuman J., Gonzalez N.M., Grados M., Vitiello B., Ritz L., Davies M., Robinson J., and McMahon D. N. Engl. J. Med. 347 (2002) 314
4. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., Arnold L.E., Posey D.J., Martin A., Ghuman J.K., Shah B., Chuang S.Z., Swiezy N.B., Gonzalez N.M., Hollway J., Koenig K., McGough J.J., Ritz L., and Vitiello B. Am. J. Psychiatry 162 (2005) 1142
5. Zuddas A., Di Martino A., Muglia P., and Cianchetti C. J. Child Adolesc. Psychopharmacol. 10 (2000) 79
6. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., and Jonkman J.H. Clin. Pharmacol. Ther. 54 (1993) 257
7. Heykants J., Huang M.L., Mannens G., Meuldermans W., Snoeck E., Van Beijsterveldt L., Van Peer A., and Woestenborghs R. J. Clin. Psychiatry 55 Suppl (1994) 13
8. Balant-Gorgia A.E., Gex-Fabry M., Genet C., and Balant L.P. Ther. Drug Monit. 21 (1999) 105
9. Aravagiri M., Marder S.R., Wirshing D., and Wirshing W.C. Pharmacopsychiatry 31 (1998) 102
10. Aravagiri M., and Marder S.R. J. Mass. Spectrom. 35 (2000) 718
11. Avenoso A., Facciola G., Salemi M., and Spina E. J. Chromatogr. B 746 (2000) 173
12. Bhatt J., Subbaiah G., and Singh S. Rapid Commun. Mass Spectrom. 20 (2006) 2109
13. Moody D.E., Laycock J.D., Huang W., and Foltz R.L. J. Anal. Toxicol. 28 (2004) 494
14. Remmerie B.M., Sips L.L., de Vries R., de Jong J., Schothuis A.M., Hooijschuur E.W., and van de Merbel N.C. J. Chromatogr. B 783 (2003) 461
15. Zhang L., Jiao Z., Yao Z., Zhong Y., Zhong M., and Yu Y. Chromatographia 61 (2005) 245
16. Yasui-Furukori N., Hidestrand M., Spina E., Facciola G., Scordo M.G., and Tybring G. Drug Metab. Dispos. 29 (2001) 1263
17. Matuszewski B.K. J. Chromatogr. B 830 (2006) 293
18. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, Center for Veterinary Medicine, Guidance for Industry Bioanalytical Method Validation (2001).
19. Jessome L.L., and Volmer D.A. LC-GC 24 (2006) 498
20. Yasui-Furukori N., Mihara K., Kondo T., Kubota T., Iga T., Takarada Y., De Vries R., Kaneko S., and Tateishi T. J. Clin. Pharmacol. 43 (2003) 122
21. Aravagiri S.R.M.M., Nuechterlein K.H., and Gitlin M.J. Ther. Drug Monitor. 25 (2003) 657